Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)

Robert J. Motzer, Naomi B. Haas, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae-Lyun Lee, Bohuslav Melichar, Brian I. Rini, Toni K. Choueiri, Milada Zemanova, Lori A Wood, Dirk Fahlenkamp, Martin Neil Reaume, Arnulf Stenzl, Weichao Bao, Paola Aimone, Christian Doehn, Paul Russo, Cora N. Sternberg

Memorial Sloan Kettering Cancer Center, New York, NY
Abramson Cancer Center, Philadelphia, PA
Aarhus University Hospital, Aarhus, Denmark
Centre Hospitalier-Universitaire Saint Andre, Bordeaux, France
Altai Regional Cancer Center, Barnaul, Russia
Regional Clinical Oncology Dispensary, Omsk, Russian Federation
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
Cleveland Clinic Taussig Cancer Insitute, Cleveland, OH
Dana-Farber Cancer Institute and Brigham and Women‘s Hospital, Boston, MA
First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
Zeisgwald Clinics Bethanien, Chemnitz, Germany
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
University Hospital Tübingen, Tübingen, Germany
Novartis Oncology, East Hanover, NJ
Novartis Pharmaceuticals AG, Basel, Switzerland
Urologikum Lubeck, Lubeck, Germany
Memorial Sloan-Kettering Cancer Center, New York, NY
San Camillo Forlanini Hospital, Rome, Italy